新型冠状病毒灭活疫苗对广东省奥密克戎变异株感染者临床结局的影响
该病例对照研究纳入2022年1月1日至5月31日广东省20家定点医院收治的1403例奥密克戎变异株感染者,分析灭活疫苗接种对肺炎发生风险和病程的影响。调整性别、年龄、基础病和报告地后,基础免疫90天以上、加强免疫90天内及加强免疫90天以上者发展为肺炎风险较低,加强免疫90天以上者病程较短。
要点
- 感染结局以非肺炎为主,占92.09%(1292例),病程中位数为18(14~22)天。
- 与无免疫史或部分免疫者相比,基础免疫90天以上者肺炎风险OR为0.52(95%CI 0.28~0.98)。
- 加强免疫90天以上者肺炎风险OR为0.40(95%CI 0.21~0.77),病程较短HR为1.26(95%CI 1.03~1.55)。
核心结论
- 新冠病毒灭活疫苗接种史影响奥密克戎变异株感染者临床结局。
研究设计与样本
- 病例对照研究,纳入2022年1月1日至5月31日广东省20家定点医院收治的1403例奥密克戎变异株感染者。
- 基于中国疾病预防控制信息系统和广东省远程医疗平台收集人口学资料、基础疾病、疫苗接种情况、末次暴露日期、感染毒株基因测序和临床结局等资料。
- 将肺炎(普通型、重型和危重型)作为病例组,非肺炎(无症状感染者和轻型)作为对照组。
主要发现
- 对象年龄M(Q1,Q3)为36(27~47)岁,男性占52.25%(733例)。
- 感染结局以非肺炎为主,占92.09%(1292例),病程M(Q1,Q3)为18(14~22)天。
- 无免疫史或部分免疫、基础免疫90天内、基础免疫90天以上、加强免疫90天内和加强免疫90天以上者分别为134例(9.55%)、39例(2.78%)、403例(28.72%)、437例(31.15%)和390例(27.80%)。
- 调整性别、年龄、基础病和报告地后,与无免疫史或部分免疫者比较,基础免疫90天以上、加强免疫90天内、加强免疫90天以上者发展为肺炎风险较低,OR(95%CI)分别为0.52(0.28~0.98)、0.39(0.21~0.73)和0.40(0.21~0.77)。
- 调整性别、年龄、基础疾病和报告地后,与无免疫史或部分免疫者相比,加强免疫90天以上者病程较短,HR(95%CI)为1.26(1.03~1.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant. Methods: A total of 1 403 Omicron-infected patients admitted to 20 designated hospitals in Guangdong Province from January 1 to May 31, 2022, were selected as subjects in this study. A case-control study was conducted to collect the demographic data, underlying disease, vaccination status, last exposure date, gene sequencing of infected strains and clinical outcomes from the China Disease Prevention and Control Information System and Guangdong telemedicine platform. Pneumonia (common, severe and critical) and non-pneumonia (asymptomatic and mild) were selected as the case group and control group. The effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant was analyzed. Results: The median age [M (Q1, Q3)] of the subjects was 36 (27-47) years old, with males accounting for 52.25% (733 cases). The main outcome of the infection was non-pneumonia, accounting for 92.09% (1 292 cases), and the duration [M (Q1, Q3)] of the disease was 18 (14-22) days. There were 134 (9.55%), 39 (2.78%), 403 (28.72%), 437 (31.15%) and 390 (27.80%) cases with no or partial vaccination, within 90 days of primary vaccination, over 90 days of primary vaccination, within 90 days of booster vaccination and over 90 days of booster vaccination, respectively. Multivariate logistic regression analysis showed that after adjusting for gender, age, underlying disease, and location of the report, compared with those with no or partial vaccination, the risk of developing pneumonia was lower in those with over 90 days of primary vaccination, within 90 days of booster vaccination and over 90 days of booster vaccination [OR (95%CI) values were 0.52 (0.28-0.98), 0.39 (0.21-0.73) and 0.40 (0.21-0.77), respectively]. Cox proportional hazard regression model analysis showed that after adjusting for gender, age, underlying disease and location of the report, the duration of the disease was shorter in those who received booster vaccinated for more than 90 days compared with that in those who had no or partial vaccination [HR (95%CI): 1.26 (1.03-1.55)]. Conclusion: The inactivated SARS-CoV-2 vaccine affects the clinical outcomes of patients infected with the Omicron variant. 目的: 了解新型冠状病毒(SARS-CoV-2)灭活疫苗对奥密克戎变异株感染者临床结局的影响。 方法: 以2022年1月1日至5月31日广东省20家定点医院收治的1 403例奥密克戎变异株感染者为对象,基于中国疾病预防控制信息系统和广东省远程医疗平台收集对象人口学资料、基础疾病资料、疫苗接种情况、末次暴露日期、感染毒株基因测序和临床结局等资料,采用病例对照研究设计,将肺炎(普通型、重型和危重型)作为病例组,非肺炎(无症状感染者和轻型)作为对照组,分析SARS-CoV-2灭活疫苗对奥密克戎变异株感染者临床结局影响。 结果: 1 403例对象年龄的M(Q1,Q3)为36(27~47)岁,男性占52.25%(733例)。感染结局以非肺炎为主,占92.09%(1 292例),病程的M(Q1,Q3)为18(14~22)d。无免疫史或部分免疫、基础免疫90 d内、基础免疫90 d以上、完成加强免疫90 d内和完成加强免疫90 d以上者分别为134(9.55%)、39(2.78%)、403(28.72%)、437(31.15%)和390(27.80%)例。多因素logistic回归分析显示:调整性别、年龄、基础病和报告地等因素后,与无免疫史或部分免疫者比较,基础免疫90 d以上、加强免疫90 d内、加强免疫90 d以上者发展为肺炎风险较低[OR(95%CI)值分别为0.52(0.28~0.98)、0.39(0.21~0.73)和0.40(0.21~0.77)]。Cox比例风险回归模型分析显示:调整性别、年龄、基础疾病和报告地等因素后,与无免疫史或部分免疫者相比,加强免疫90 d以上者病程较短[HR(95%CI):1.26(1.03~1.55)]。 结论: 新冠病毒灭活疫苗接种史影响奥密克戎变异株感染者临床结局。.
引用
- Hu P, Lin DE, Zhu Q, et al. [Effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant in Guangdong Province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2023. PMID: 37482735. doi:10.3760/cma.j.cn112150-20220802-00775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。